Bevacizumab biosimilar - Apobiologix
Latest Information Update: 10 Feb 2017
At a glance
- Originator Apobiologix
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 10 Feb 2017 Clinical trials in Cancer (IV) (Apobiologix pipeline, February 2017)